Published in Mol Pain on May 28, 2010
Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther (2011) 1.90
Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther (2013) 1.73
Intraganglionic AAV6 results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats. PLoS One (2013) 1.51
Biology of adeno-associated viral vectors in the central nervous system. Front Mol Neurosci (2014) 1.04
Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat (2014) 0.96
Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy. Proc Natl Acad Sci U S A (2016) 0.92
Gene therapy for the treatment of chronic peripheral nervous system pain. Neurobiol Dis (2012) 0.91
Clinical applications involving CNS gene transfer. Adv Genet (2014) 0.89
In vivo gene knockdown in rat dorsal root ganglia mediated by self-complementary adeno-associated virus serotype 5 following intrathecal delivery. PLoS One (2012) 0.88
Molecular anatomy of the gut-brain axis revealed with transgenic technologies: implications in metabolic research. Front Neurosci (2013) 0.86
Visualization of spinal afferent innervation in the mouse colon by AAV8-mediated GFP expression. Neurogastroenterol Motil (2012) 0.84
Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs. Mol Pain (2014) 0.80
The assessment of adeno-associated vectors as potential intrinsic treatments for brainstem axon regeneration. J Gene Med (2012) 0.80
Supraspinal gene transfer by intrathecal adeno-associated virus serotype 5. Front Neuroanat (2014) 0.79
Current gene therapy using viral vectors for chronic pain. Mol Pain (2015) 0.79
Intraneural convection enhanced delivery of AAVrh20 for targeting primary sensory neurons. Mol Cell Neurosci (2014) 0.78
Syntaxin 8 modulates the post-synthetic trafficking of the TrkA receptor and inflammatory pain transmission. J Biol Chem (2014) 0.78
High cerebrospinal fluid levels of interleukin-10 attained by AAV in dogs. Gene Ther (2014) 0.76
Adeno-associated Virus Vectors Efficiently Transduce Mouse and Rabbit Sensory Neurons Coinfected with Herpes Simplex Virus 1 following Peripheral Inoculation. J Virol (2016) 0.75
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Intrathecal morphine in mice: a new technique. Eur J Pharmacol (1980) 5.99
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med (1999) 5.50
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem (2001) 3.15
Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery (1998) 2.99
The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol (2006) 2.94
Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med (2003) 2.43
Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience (2006) 2.19
A method to perform direct transcutaneous intrathecal injection in rats. J Pharmacol Toxicol Methods (1994) 2.16
Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo. Nature (1980) 2.08
Intense isolectin-B4 binding in rat dorsal root ganglion neurons distinguishes C-fiber nociceptors with broad action potentials and high Nav1.9 expression. J Neurosci (2006) 2.05
Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol (2005) 1.97
Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther (2003) 1.94
P2X3 is expressed by DRG neurons that terminate in inner lamina II. Eur J Neurosci (1998) 1.85
Spinal delivery of analgesics in experimental models of pain and analgesia. Adv Drug Deliv Rev (2003) 1.84
Glial cell line-derived neurotrophic factor is a survival factor for isolectin B4-positive, but not vanilloid receptor 1-positive, neurons in the mouse. J Neurosci (2002) 1.81
Lumbar catheterization of the spinal subarachnoid space in the rat. J Neurosci Methods (1996) 1.74
Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci U S A (2008) 1.73
Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol (2006) 1.64
Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol Pain (2009) 1.39
Intermittent lumbar puncture in rats: a novel method for the experimental study of opioid tolerance. Anesth Analg (2006) 1.33
Adeno-associated viral transfer of opioid receptor gene to primary sensory neurons: a strategy to increase opioid antinociception. Proc Natl Acad Sci U S A (2003) 1.32
Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J Virol (2002) 1.30
AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol Ther (2005) 1.20
A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum Gene Ther (1999) 1.13
Nerve injury-induced tactile allodynia is mediated via ascending spinal dorsal column projections. Pain (2001) 1.08
In vivo transduction of cerebellar Purkinje cells using adeno-associated virus vectors. Mol Ther (2000) 1.07
Lumbar catheterization of the subarachnoid space with a 32-gauge polyurethane catheter in the rat. Eur J Pain (2000) 1.07
Chronic intrathecal infusions after spinal cord injury cause scarring and compression. Microsc Res Tech (2001) 1.04
Intrathecal gene transfer by adeno-associated virus for pain. Curr Opin Mol Ther (2005) 0.99
Neurochemical characterization of insulin receptor-expressing primary sensory neurons in wild-type and vanilloid type 1 transient receptor potential receptor knockout mice. J Comp Neurol (2007) 0.91
Intrathecal catheterization in the rat. Improved technique for morphologic analysis of drug-induced injury. Anesthesiology (1996) 0.87
Decreased paralysis and better motor coordination with microspinal versus PE10 intrathecal catheters in pain study rats. Anesth Analg (1997) 0.82
In vivo control of NMDA receptor transcript level in motoneurons by viral transduction of a short antisense gene. Brain Res Mol Brain Res (2001) 0.78
Treatment of increased intracranial pressure: a comparison of different hyperosmotic agents and the use of thiopental. Neurosurgery (1979) 0.78
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Harnessing a high cargo-capacity transposon for genetic applications in vertebrates. PLoS Genet (2006) 2.99
Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood (2009) 2.15
RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues. Mol Ther (2005) 1.98
Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. Nat Protoc (2007) 1.73
Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. Proc Natl Acad Sci U S A (2005) 1.72
Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet (2005) 1.60
Peripheral mechanisms of pain and analgesia. Brain Res Rev (2008) 1.55
Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther (2004) 1.44
Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells (2007) 1.44
Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood (2005) 1.40
Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med (2007) 1.33
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain (2003) 1.25
Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther (2009) 1.24
A picornaviral 2A-like sequence-based tricistronic vector allowing for high-level therapeutic gene expression coupled to a dual-reporter system. Mol Ther (2005) 1.23
Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I. Mol Ther (2007) 1.21
alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther (2002) 1.20
The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet (2011) 1.18
Dynamic gene expression after systemic delivery of plasmid DNA as determined by in vivo bioluminescence imaging. Hum Gene Ther (2005) 1.18
Sleeping beauty transposition from nonintegrating lentivirus. Mol Ther (2009) 1.18
An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat Commun (2013) 1.17
Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis. Pharmacol Ther (2009) 1.15
Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis. PLoS Genet (2013) 1.15
Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis (2011) 1.14
The analgesic effect of low dose focal irradiation in a mouse model of bone cancer is associated with spinal changes in neuro-mediators of nociception. Pain (2005) 1.09
A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver. Hepatology (2008) 1.09
Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. Blood (2006) 1.08
Characterization of a novel peripheral pro-lipolytic mechanism in mice: role of VGF-derived peptide TLQP-21. Biochem J (2012) 1.06
Conditional gene expression in the mouse using a Sleeping Beauty gene-trap transposon. BMC Biotechnol (2006) 1.05
Transcutaneous electrical nerve stimulation activates peripherally located alpha-2A adrenergic receptors. Pain (2005) 1.03
Protein kinase C mediates the synergistic interaction between agonists acting at alpha2-adrenergic and delta-opioid receptors in spinal cord. J Neurosci (2009) 1.02
Coexpression of alpha 2A-adrenergic and delta-opioid receptors in substance P-containing terminals in rat dorsal horn. J Comp Neurol (2009) 1.02
DNA transposons for modification of human primary T lymphocytes. Methods Mol Biol (2009) 1.01
A role for CD28 in lymphopenia-induced proliferation of CD4 T cells. J Immunol (2004) 1.00
Mechanism of cancer pain. Mol Interv (2010) 1.00
Designing protein dimerizers: the importance of ligand conformational equilibria. J Am Chem Soc (2003) 1.00
Lung-directed gene therapy in mice using the nonviral Sleeping Beauty transposon system. Nat Protoc (2007) 0.99
Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther (2002) 0.99
Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain (2005) 0.97
Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain (2003) 0.97
Activation of spinal microglia in a murine model of peripheral inflammation-induced, long-lasting contralateral allodynia. Neurosci Lett (2008) 0.97
Agmatine: clinical applications after 100 years in translation. Drug Discov Today (2013) 0.96
Cytotoxicity associated with artemis overexpression after lentiviral vector-mediated gene transfer. Hum Gene Ther (2010) 0.95
Protection of mice from methotrexate toxicity by ex vivo transduction using lentivirus vectors expressing drug-resistant dihydrofolate reductase. J Pharmacol Exp Ther (2007) 0.94
Sleeping Beauty-mediated transposition and long-term expression in vivo: use of the LoxP/Cre recombinase system to distinguish transposition-specific expression. Mol Ther (2005) 0.94
Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. Mol Genet Metab (2012) 0.93
Clonidine and dexmedetomidine produce antinociceptive synergy in mouse spinal cord. Anesthesiology (2009) 0.92
Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons. Hum Gene Ther (2010) 0.92
Awakening gene therapy with Sleeping Beauty transposons. Curr Opin Pharmacol (2005) 0.91
DPDPE-UK14,304 synergy is retained in mu opioid receptor knockout mice. Pain (2003) 0.91
Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System. Mol Cancer (2011) 0.89
Real-time in vivo imaging of stem cells following transgenesis by transposition. Mol Ther (2005) 0.89
The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors. ACS Chem Neurosci (2012) 0.89
Correction of DNA protein kinase deficiency by spliceosome-mediated RNA trans-splicing and sleeping beauty transposon delivery. Mol Ther (2007) 0.88
Effects of agmatine, interleukin-10, and cyclosporin on spontaneous pain behavior after excitotoxic spinal cord injury in rats. J Pain (2003) 0.88
Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate. J Med Chem (2003) 0.87
Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration. Eur J Pharmacol (2008) 0.87
Proteomic analysis uncovers novel actions of the neurosecretory protein VGF in nociceptive processing. J Neurosci (2009) 0.86
Cardioprotective mechanisms activated in response to myocardial ischemia. Mol Cell Biomech (2011) 0.86
Effects of peripheral nerve injury on delta opioid receptor (DOR) immunoreactivity in the rat spinal cord. Neurosci Lett (2004) 0.86
Cellular immune response against firefly luciferase after sleeping beauty-mediated gene transfer in vivo. Hum Gene Ther (2014) 0.86
OCT2 and MATE1 provide bidirectional agmatine transport. Mol Pharm (2010) 0.85
Liver-directed gene therapy using the sleeping beauty transposon system. Methods Mol Biol (2008) 0.85
Experimental animal models of muscle pain and analgesia. Exerc Sport Sci Rev (2003) 0.85
ST91 [2-(2,6-diethylphenylamino)-2-imidazoline hydrochloride]-mediated spinal antinociception and synergy with opioids persists in the absence of functional alpha-2A- or alpha-2C-adrenergic receptors. J Pharmacol Exp Ther (2007) 0.84
Alpha-2-adrenergic and opioid receptor additivity in rat locus coeruleus neurons. Neurosci Lett (2004) 0.84
Neuropharmacokinetic and dynamic studies of agmatine (decarboxylated arginine). Ann N Y Acad Sci (2003) 0.84
Identification of some lectin IB4 binding proteins in rat dorsal root ganglia. Neuroreport (2004) 0.83
In vitro functional correction of the mutation responsible for murine severe combined immune deficiency by small fragment homologous replacement. Hum Gene Ther (2006) 0.83
Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. Hum Gene Ther (2002) 0.83
Quantitative analysis of α-L-iduronidase expression in immunocompetent mice treated with the Sleeping Beauty transposon system. PLoS One (2013) 0.83
Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse. J Pharmacol Exp Ther (2005) 0.83
Immunoneutralization of agmatine sensitizes mice to micro-opioid receptor tolerance. J Pharmacol Exp Ther (2009) 0.82
Release of tritiated agmatine from spinal synaptosomes. Neuroreport (2006) 0.82